Biovie is trading 9.81% down at $1.93, with no verified company-specific announcement dated August 24 or August 25 explaining the decline.

  • The stock closed at $2.14 on August 24, 2026.
  • The latest major update remains the August 6 Parkinson’s trial results; the August 14 S-1/A filing does not establish a direct cause.
  • Broader indexes are positive, so market sentiment does not clearly explain the drop.